Gilead Sciences [NASDAQ: GILD] Plans to Expand Availability of Remdesivir in India

Gilead Sciences Inc. [NASDAQ: GILD] revealed that it is preparing to increase the availability of Remdesivir in India. India is currently experiencing the severe impact of the third wave of coronavirus. The firm has disclosed that it has decided to offer technical assistance to its voluntary licensing partners.

This is the support for the addition of new local manufacturing facilities and the contribution of active pharmaceutical ingredients (API) to quickly speed up the production of Remdesivir. Remdesivir has got authorization for restricted emergency use for the cure of alleged or laboratory validated COVID-19 in grownups and children hospitalized with serious disease.

Additionally, Gilead is also planning to donate at least 450,000 vials of Veklury (Remdesivir) to assist in tackling the urgent needs of Indian sufferers. It will offer support to its licensees to extend their local manufacturing capacity. Currently, the strong wave of COVID-19 has badly affected the lives of Indians. The health system of Indian is also facing huge pressure.

Gilead has taken a major step to curb the impact of COVID-19. Gilead has seven licensees based in India. They have significantly speed up the production of Remdesivir by scaling up their batch sizes. They are also adding new production facilities and/or onboarding local contract producers across the country.

It has been anticipated that these efforts will increase the accessibility of Remdesivir in the coming weeks. The voluntary licensing program of Gilead for Remdesivir, created in May 2020, has already aided access to the drug for more than 2.3 million people in more than 60 low- and middle-income countries.